Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD

Thirty patients with a body mass index of 40.7 ± 9.3 kg/m were analyzed for treatment outcomes.

• Combination therapy of endoscopic gastric remodeling (EGR) with glucagon-like peptide-1 receptor agonist (GLP-1RA) resulted in a 55 ± 23% reduction in alanine aminotransferase levels compared to 29 ± 22% in EGR monotherapy (p = 0.008).
• The NAFLD fibrosis score decreased by 181 ± 182% in the combination therapy group versus 30 ± 83% in the monotherapy group (p = 0.04).
• Liver stiffness measurement showed a reduction of 54 ± 12% in combination therapy compared to 14 ± 45% in monotherapy (p = 0.05).
• There were significant reductions in hemoglobin A1c and insulin resistance indicators in the combination therapy group (p < 0.05).
• At 12 months, the combination therapy group achieved an average total weight loss of 18.2 ± 6.6%, while the monotherapy group had 9.6 ± 3.3% (p = 0.004).

AI simplified